Simvastatin with or without Ezetimibe in Familial Hypercholesterolemia
Open accessThe DOI matches its Crossref record; 34 of the 34 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Ezetimibe, a cholesterol-absorption inhibitor, reduces levels of low-density lipoprotein (LDL) cholesterol when added to statin treatment. However, the effect of ezetimibe on the progression of atherosclerosis remains unknown. METHODS: We conducted a double-blind, randomized, 24-month trial comparing the effects of daily therapy with 80 mg of simvastatin either with placebo or with 10 mg of ezetimibe in 720 patients with familial hypercholesterolemia. Patients underwent B-mode ultrasonography to assess the intima-media thickness of the walls of the carotid and femoral arteries. The primary outcome measure was the change in the mean carotid-artery intima-media thickness, which was defined as the average of the means of the far-wall intima-media thickness of the right and left common carotid arteries, carotid bulbs, and internal carotid arteries. RESULTS: The primary outcome, the mean (+/-SE) change in the carotid-artery intima-media thickness, was 0.0058+/-0.0037 mm in the simvastatin-only group and 0.0111+/-0.0038 mm in the simvastatin-plus-ezetimibe (combined-therapy) group (P=0.29). Secondary outcomes (consisting of other variables regarding the intima-media thickness of the carotid and femoral arteries) did not differ significantly between the two groups. At the end of the study, the mean (+/-SD) LDL cholesterol level was 192.7+/-60.3 mg per deciliter (4.98+/-1.56 mmol per liter) in the simvastatin group and 141.3+/-52.6 mg per deciliter (3.65+/-1.36 mmol per liter) in the combined-therapy group (a between-group difference of 16.5%, P<0.01). The differences between the two groups in reductions in levels of triglycerides and C-reactive protein were 6.6% and 25.7%, respectively, with greater reductions in the combined-therapy group (P<0.01 for both comparisons). Side-effect and safety profiles were similar in the two groups. CONCLUSIONS: In patients with familial hypercholesterolemia, combined therapy with ezetimibe and simvastatin did not result in a significant difference in changes in intima-media thickness, as compared with simvastatin alone, despite decreases in levels of LDL cholesterol and C-reactive protein. (ClinicalTrials.gov number, NCT00552097 [ClinicalTrials.gov].).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Although the earlier ENHANCE trial could not confirm that an addition of ezetimibe to statins significantly reduces intima-media thickness in patients with familial hypercholesterolemia, the SHARP and SEAS trials highlight ezetimibe’s role in the prevention of ischaemic cardiovascular events [62–65].”
From Established and Emerging Lipid-Lowering Drugs for Primary and Secondary Cardiovascular Prevention (2023) · cites this paper as [65]
In the citing paper
“the SHARP and SEAS trials highlight ezetimibe’s role in the prevention of ischaemic cardiovascular events [62–65].”
From Established and Emerging Lipid-Lowering Drugs for Primary and Secondary Cardiovascular Prevention (2023) · cites this paper as [65]
Citations
Cites
Intensive versus Moderate Lipid Lowering with Statins after Acute Coronary Syndromes
Cannon, C. P., Braunwald, E., McCabe, C. H., Rader, D. J., Rouleau, J. L., Belder, R., Joyal, S. V., Hill, K. A., Pfeffer, M. A., & Skene, A. M. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040583 · Cited by 4,938
Intensive Lipid Lowering with Atorvastatin in Patients with Stable Coronary Disease
LaRosa, J. C., Grundy, S. M., Waters, D. D., Shear, C., Barter, P., Fruchart, J.-C., Gotto, A. M., Greten, H., Kastelein, J. J. P., Shepherd, J., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050461 · Cited by 3,489
Self-citationBots, M. L., Hoes, A. W., Koudstaal, P. J., Hofman, A., & Grobbee, D. E. (1997) · Circulation · doi:10.1161/01.cir.96.5.1432 · Cited by 2,345
Self-citationNiemann-Pick C1 Like 1 Protein Is Critical for Intestinal Cholesterol Absorption
Altmann, S. W., Davis, H. R., Zhu, L.-J., Yao, X., Hoos, L. M., Tetzloff, G., Iyer, S. P. N., Maguire, M., Golovko, A., Zeng, M., et al. (2004) · Science · doi:10.1126/science.1093131 · Cited by 1,577
Pedersen, T. R. (2005) · JAMA · doi:10.1001/jama.294.19.2437 · Cited by 1,548
Self-citationBuchwald, H., Varco, R. L., Matts, J. P., Long, J. M., Fitch, L. L., Campbell, G. S., Pearce, M. B., Yellin, A. E., Edmiston, W. A., Smink, R. D., et al. (1990) · New England Journal of Medicine · doi:10.1056/nejm199010043231404 · Cited by 1,001
Smilde, T., van Wissen, S., Awollersheim, H., Trip, M., Kastelein, J., & Stalenhoef, A. (2001) · The Lancet · doi:10.1016/s0140-6736(00)04053-8 · Cited by 918
Self-citationTaylor, A. J., Sullenberger, L. E., Lee, H. J., Lee, J. K., & Grace, K. A. (2004) · Circulation · doi:10.1161/01.cir.0000148955.19792.8d · Cited by 890
The safety of statins in clinical practice
Armitage, J. (2007) · The Lancet · doi:10.1016/s0140-6736(07)60716-8 · Cited by 833
Cited by
Items 201–300 of 1,000
Javed, U., DEEDWANIA, P. C., Bhatt, D. L., Cannon, C. P., Dai, D. W. H., Hernandez, A. F., Peterson, E. D., & Fonarow, G. C. (2011) · American Heart Journal · doi:10.1016/j.ahj.2010.12.014 · Cited by 56
Slätis, K., Gåfvels, M., Kannisto, K., Ovchinnikova, O., Paulsson-Berne, G., Parini, P., Jiang, Z.-Y., & Eggertsen, G. (2010) · Journal of Lipid Research · doi:10.1194/jlr.m009308 · Cited by 56
Henningsen, K. M. A., Nilsson, B., Brüünsgaard, H., Chen, X., Pedersen, B. K., & Svendsen, J. H. (2009) · Scandinavian Cardiovascular Journal · doi:10.1080/14017430802653676 · Cited by 61
Lipid Metabolism in Treated HIV Infection
Dubé, M. P., & Cadden, J. J. (2011) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2011.04.004 · Cited by 60
Zhao, Z., Du, S., Shen, S., Luo, P., Ding, S., Wang, G., & Wang, L. (2019) · Medicine · doi:10.1097/md.0000000000014400 · Cited by 54
“In addition, treatment with ezetimibe alone lowered LDL-C level by a small extent, 19% reduction from baseline as showed by our lipid outcomes, which, according to previous meta-analysis,([43]) yielded a slight decrease in CV risk.”
ResultMolecular pathways and agents for lowering LDL-cholesterol in addition to statins
Costet, P. (2010) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2010.02.006 · Cited by 61
Prevention and Treatment of Atherosclerosis: A Practitioner's Guide for 2008
Lewis, S. J. (2008) · The American Journal of Medicine · doi:10.1016/j.amjmed.2008.10.016 · Cited by 61
Pleiotropic effects of ezetimibe: Do they really exist?
Kalogirou, M., Tsimihodimos, V., & Elisaf, M. (2010) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2010.02.003 · Cited by 59
“Nevertheless, in the recently published Ezetimibe and Simvastatin in Hypercholesterolemia Enhances Atherosclerosis Regression (ENHANCE) study the use of ezetimibe in patients with familial hypercholesterolemia as add-on therapy to simvastatin failed to produce significant changes in the carotid intima media thickness,…”
BackgroundNicholls, S. J., Borgman, M., Nissen, S. E., Raichlen, J. S., Ballantyne, C. M., Barter, P. J., Chapman, M. J., Erbel, R. M., & Libby, P. (2011) · Current Medical Research and Opinion · doi:10.1185/03007995.2011.570746 · Cited by 62
Dynamic interactions of n-3 and n-6 fatty acid nutrients
Lands, B., Bibus, D. M., & Stark, K. D. (2017) · Prostaglandins Leukotrienes and Essential Fatty Acids · doi:10.1016/j.plefa.2017.01.012 · Cited by 58
The Influence of Big (Clinical) Data and Genomics on Precision Medicine and Drug Development
Denny, J. C., Driest, S. L. V., Wei, W., & Roden, D. M. (2017) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.951 · Cited by 56
“However, its efficacy in reducing cardiovascular disease had been in doubt 15 until an MR study demonstrated that individuals with LOF variants in NPC1L1 had both reduced LDL-cholesterol levels and a 53% reduction in cardiovascular disease.”
BackgroundKizer, J. R., Madias, C., Wilner, B., Vaughan, C. J., Mushlin, A. I., Trushin, P., Gotto, A. M., & Pasternak, R. C. (2010) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2009.12.051 · Cited by 52
Catry, É., Pachikian, B. D., Salazar, N., Neyrinck, A. M., Cani, P. D., & Delzenne, N. M. (2015) · Life Sciences · doi:10.1016/j.lfs.2015.04.004 · Cited by 57
Ezetimibe Attenuates Atherosclerosis Associated with Lipid Reduction and Inflammation Inhibition
Tie, C., Gao, K., Zhang, N., Zhang, S., Shen, J., Xie, X., & Wang, J.-A. (2015) · PLoS ONE · doi:10.1371/journal.pone.0142430 · Cited by 53
“However, some of the clinical studies, such as ENHANCE [4], SANDS [7] and VYCTOR [8] trials demonstrated that this combination therapy failed to show beneficial effect on carotid intima-media thickness.”
ResultA Review of Lipid Management in Primary and Secondary Prevention
Dembowski, E., & Davidson, M. H. (2009) · Journal of Cardiopulmonary Rehabilitation and Prevention · doi:10.1097/hcr.0b013e318192754e · Cited by 53
Bhattacharyya, O. K., Shah, B. R., & Booth, G. L. (2008) · Canadian Medical Association Journal · doi:10.1503/cmaj.080554 · Cited by 52
“A recent study of the benefit of adding ezetimibe to statins for patients with familial hypercholesterolemia failed to show any benefit; thus, the role of combination therapy remains unclear.(32,33) Statins are well tolerated and well-studied medications whose benefits largely outweigh the risks.”
BackgroundSurrogate markers in clinical trials—Challenges and opportunities
Duivenvoorden, R., de Groot, E., Stroes, E. S. G., & Kastelein, J. J. P. (2008) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2008.12.009 · Cited by 62
Self-citationCombination therapy in dyslipidemia: Where are we now?
Catapano, A. L., Farnier, M., Foody, J. M., Toth, P. P., Tomassini, J. E., Brudi, P., & Tershakovec, A. M. (2014) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2014.09.026 · Cited by 55
“This effect of atorvastatin was not evident either in studies of postmenopausal women [71,72], or in patients with FH treated with atorvastatin only in the Rating Atherosclerotic Disease Change by Imaging with a New CETP Inhibitor (RADIANCE) trial who had received substantial statin treatment prior to enrollment with…”
BackgroundInfluentialInflammation and beyond: new directions and emerging drugs for treating atherosclerosis
Bertrand, M.-J., & Tardif, J. (2016) · Expert Opinion on Emerging Drugs · doi:10.1080/14728214.2017.1269743 · Cited by 59
Krysiak, R. G., Żmuda, W., & Okopień, B. (2011) · Journal of Internal Medicine · doi:10.1111/j.1365-2796.2011.02394.x · Cited by 52
Effect of adjunct metformin treatment on levels of plasma lipids in patients with type 1 diabetes
Lund, S. S., Tarnow, L., Astrup, A. S., Hovind, P., Jacobsen, P. K., Alibegovic, A. C., Parving, I., Pietraszek, L., Frandsen, M., Rossing, P., et al. (2009) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2009.01079.x · Cited by 53
Choudhry, N. K., Dugani, S., Shrank, W. H., Polinski, J. M., Stark, C. E., Gupta, R., Prabhakaran, D., Brill, G., & Jha, P. (2014) · Health Affairs · doi:10.1377/hlthaff.2013.0388 · Cited by 51
Santos, R. D., & Nasir, K. (2008) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2008.12.017 · Cited by 59
Carr, T. P., Krogstrand, K. L. S., Schlegel, V. L., & Fernández, M. L. (2009) · Journal of Nutrition · doi:10.3945/jn.109.106328 · Cited by 53
“Statin drugs have been used for 2 decades as an effective cholesterol-lowering therapy, but they can cause severe adverse effects in a considerable proportion of patients (3,4).”
BackgroundLongitudinal Ultrasound Evaluation of Carotid Atherosclerosis in One, Two and Three Dimensions
Mallett, C. L., House, A. A., Spence, J. D., Fenster, A., & Párraga, G. (2008) · Ultrasound in Medicine & Biology · doi:10.1016/j.ultrasmedbio.2008.09.008 · Cited by 51
“Similarly, in the ENHANCE study, a decrease in LDL cholesterol was observed in the combined-treatment group, but there was no difference in IMT between treatments (Kastelein et al. 2008).”
ResultTaylor, A., Sullenberger, L., Lee, H., Lee, J., & Grace, K. A. (2008) · The Physician and Sportsmedicine · doi:10.3810/psm.2008.12.22 · Cited by 51
Descamps, O. S., SUTTER, J. D., Guillaume, M., & Missault, L. H. (2011) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2011.06.010 · Cited by 56
Squalene monooxygenase - a target for hypercholesterolemic therapy
Belter, A., Skupińska, M., Giel-Pietraszuk, M., Grabarkiewicz, T., Rychlewski, L., & Barciszewski, J. (2011) · Biological Chemistry · doi:10.1515/bc.2011.195 · Cited by 53
Drug Treatment of Hyperlipidaemia: A Guide to the Rational Use of Lipid-Lowering Drugs
Toth, P. P. (2010) · Drugs · doi:10.2165/10898610-000000000-00000 · Cited by 57
Improved efficacy for ezetimibe and rosuvastatin by attenuating the induction of PCSK9
Ason, B., Tep, S., Davis, J. H. R., Xu, Y., Tetzloff, G., Galinski, B., Soriano, F., Dubinina, N., Zhu, L., Stefanni, A., et al. (2011) · Journal of Lipid Research · doi:10.1194/jlr.m013664 · Cited by 49
Combination therapy of statin and ezetimibe for the treatment of familial hypercholesterolemia
Hamilton-Craig (2010) · Vascular Health and Risk Management · doi:10.2147/vhrm.s13496 · Cited by 56
The Relationships of Markers of Cholesterol Homeostasis with Carotid Intima-Media Thickness
Weingärtner, O., Pinsdorf, T., Rogacev, K. S., Blömer, L., Grenner, Y., Gräber, S., Ulrich, C., Girndt, M., Böhm, M., Fliser, D., et al. (2010) · PLoS ONE · doi:10.1371/journal.pone.0013467 · Cited by 48
Ran, D., Nie, H.-J., Gao, Y.-L., Deng, S., Du, J., Liu, Y., Jing, X., & She, Q. (2017) · International Journal of Cardiology · doi:10.1016/j.ijcard.2017.02.099 · Cited by 51
Hibi, K., Sonoda, S., Kawasaki, M., Otsuji, Y., Murohara, T., Ishii, H., Sato, K., Koshida, R., Ozaki, Y., Sata, M., et al. (2017) · Circulation Journal · doi:10.1253/circj.cj-17-0598 · Cited by 49
Unique features of dyslipidemia in women across a lifetime and a tailored approach to management
Patel, N., Mittal, N., Wilkinson, M. J., & Taub, P. R. (2024) · American Journal of Preventive Cardiology · doi:10.1016/j.ajpc.2024.100666 · Cited by 47
Uemura, Y., Watarai, M., Ishii, H., Koyasu, M., Takemoto, K., Yoshikawa, D., Shibata, R., Matsubara, T., & Murohara, T. (2011) · Journal of Cardiology · doi:10.1016/j.jjcc.2011.09.001 · Cited by 47
“Simvastatin was the statin combined with ezetimibe in revious large-scale trials [7,33].”
BackgroundInfluentialAhles, S., Stevens, Y., Joris, P. J., Vauzour, D., Adam, J. J., de Groot, E., & Plat, J. (2020) · Nutrients · doi:10.3390/nu12082475 · Cited by 50
“For image analyses, eTrack software (Sonix Touch version) was used by an analyst blinded for timepoints and treatments [29].”
MethodHelkkula, P., Kiiskinen, T., Havulinna, A. S., Karjalainen, J., Koskinen, S., Salomaa, V., Daly, M. J., Palotie, A., Surakka, I., Ripatti, S., et al. (2021) · PLOS Genetics · doi:10.1371/journal.pgen.1009501 · Cited by 47
Coma, A. V., Zara, C., Godman, B., Agustí, A., Diogène, E., Wettermark, B., & Haycox, A. R. (2009) · Expert Review of Pharmacoeconomics & Outcomes Research · doi:10.1586/erp.09.58 · Cited by 48
Lardizabal, J. A., & DEEDWANIA, P. C. (2011) · Cardiology Clinics · doi:10.1016/j.ccl.2010.10.002 · Cited by 48
Medication Discontinuation in the IMPROVE-IT Trial
Návar, A. M., Roe, M. T., White, J. A., Cannon, C. P., Lokhnygina, Y. V., Newby, L. K., Giugliano, R. P., Tershakovec, A. M., Braunwald, E., Califf, R. M., et al. (2019) · Circulation Cardiovascular Quality and Outcomes · doi:10.1161/circoutcomes.118.005041 · Cited by 47
Familial Hypercholesterolemia: Present and Future Management
Sjouke, B., Kusters, D. M., Kastelein, J. J. P., & Hovingh, G. K. (2011) · Current Cardiology Reports · doi:10.1007/s11886-011-0219-9 · Cited by 50
Self-citationRecent Clinical Studies of the Effects of Lipid-Modifying Therapies
Gotto, A. M., & Moon, J. E. (2012) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2012.04.003 · Cited by 49
Pharmacotherapies for lipid modification: beyond the statins
Gotto, A. M., & Moon, J. E. (2013) · Nature Reviews Cardiology · doi:10.1038/nrcardio.2013.117 · Cited by 46
Atualização da Diretriz Brasileira de Hipercolesterolemia Familiar – 2021
Izar, M. C. D. O., Rocha, V. Z., Bertolami, A., Santos, R. D., Lottenberg, A. M., Assad, M. H. V., Saraiva, J. F. K., Chacra, A. P. M., Martinez, T. L. D. R., Bahia, L., et al. (2021) · Arquivos Brasileiros de Cardiologia · doi:10.36660/abc.20210788 · Cited by 67
Chow, D. C., Chen, H., Glesby, M. J., Busti, A. J., Souza, S. A., Andersen, J., Kohrs, S., Wu, J. W., & Koletar, S. L. (2009) · AIDS · doi:10.1097/qad.0b013e32833068e3 · Cited by 47
“Lipid profile Cholesterol, total (mg/dl) 244 (218, 272) 243 (222, 267) LDL-C (mg/dl) 160 (134, 181) 161 (138, 183) HDL-C (mg/dl) 49 (42, 56) 49 (41, 56) Non-HDL-C (mg/dl) 197 (170, 222) 197 (172, 218) Triglyceride (mg/dl) 158 (116, 201) 168 (116, 203) Apo B (mg/dl) 118 (108, 130) 120 (110, 131) hsCRP (mg/dl) 4.45 (1.1…”
BackgroundInfluentialEffects of ezetimibe on atherosclerosis in preclinical models
Davis, H. R., Lowe, R. S., & Neff, D. (2011) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2011.02.010 · Cited by 48
The Uses of Biomarkers in Drug Development
Hurko, O. (2009) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2009.04946.x · Cited by 48
Ezetimibe – a new approach in hypercholesterolemia management
Suchy, D., Łabuzek, K., Stadnicki, A., & Okopień, B. (2011) · Pharmacological Reports · doi:10.1016/s1734-1140(11)70698-3 · Cited by 44
“did not observe any differences between the primary end points as measured by changes in the carotid intima-media thickness (CIMT) between familial hypercholesterolemic subjects who were randomly assigned a high dose of simvastatin (80 mg daily) plus ezetimibe (10 mg daily) or the same dose of simvastatin plus placebo…”
BackgroundAdolphe, A., Cook, L. S., & Huang, X. (2009) · Mayo Clinic Proceedings · doi:10.4065/84.3.221 · Cited by 44
Acyltransferase inhibitors: a patent review (2010–present)
Ohshiro, T., & Tomoda, H. (2014) · Expert Opinion on Therapeutic Patents · doi:10.1517/13543776.2014.989833 · Cited by 45
“However, the ENHANCE trial demonstrated that combined therapy with ezetimibe and simvastatin did not lead to significant changes in the progression of atherosclerosis over that with simvastatin only therapy in patients with heterozygous familial hypercholesterolemia (FH) [11].”
BackgroundSerban, M.-C., Banach, M., & Mikhailidis, D. P. (2016) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2016.1118055 · Cited by 44
“by carotid intima-media thickness in FH patients.[38,39] However, these trials had several design limitations and later statin + ezetimibe trials showed that adding eze-”
BackgroundHsieh, H.-C., Hsu, J. C., & Lu, C. Y. (2017) · BMJ Open · doi:10.1136/bmjopen-2016-014150 · Cited by 46
Faggiano, P. M., Pirillo, A., Griffo, R., Ambrosetti, M., Pedretti, R. F. E., Scorcu, G., Werren, M., Febo, O., Malfatto, G., Favretto, G., et al. (2017) · International Journal of Cardiology · doi:10.1016/j.ijcard.2017.10.105 · Cited by 48
Cunnington, M. S., Mayosi, B. M., Hall, D. H., Avery, P. J., Farrall, M., Vickers, M. A., Watkins, H. C., & Keavney, B. D. (2008) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2008.06.025 · Cited by 44
Oswald, S., zu Schwabedissen, H. E. M., Nassif, A., Modeß, C., Desta, Z., Ogburn, E. T., Mostertz, J., Keiser, M., Jia, J., Hubeny, A., et al. (2012) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2011.255 · Cited by 44
Developing Medicines That Mimic the Natural Successes of the Human Genome
Kathiresan, S. (2015) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2015.02.049 · Cited by 44
“progression, as assessed by carotid intima-media thickness (11).”
MethodIp, C.-K., Jin, D.-M., Gao, J.-J., Meng, Z., Meng, J., Tan, Z., Wang, J.-F., & Geng, D.-F. (2015) · International Journal of Cardiology · doi:10.1016/j.ijcard.2015.04.228 · Cited by 43
Tendolkar, I., Enajat, M., Zwiers, M. P., van Wingen, G. A., de Leeuw, F., van Kuilenburg, J. T., Bouwels, L., Pop, G., & Pop‐Purceleanu, M. (2011) · International Journal of Geriatric Psychiatry · doi:10.1002/gps.2688 · Cited by 44
Early diagnosis and treatment of familial hypercholesterolemia: improving patient outcomes
Alonso, R., Mata, P., Zambón, D., Mata, N., & Fuentes, F. J. (2013) · Expert Review of Cardiovascular Therapy · doi:10.1586/erc.13.7 · Cited by 44
Ezetimibe Therapy for Dyslipidemia: An Update
Katsiki, N., Theocharidou, E., Karagiannis, A. I., Athyros, V. G., & Mikhailidis, D. P. (2013) · Current Pharmaceutical Design · doi:10.2174/13816128113199990314 · Cited by 44
Imaging Atherosclerosis by Carotid Intima-media Thickness in vivo: How to, Where and in Whom ?
Onuţ, R., Balanescu, A. P. S., Constantinescu, D., Câlmâc, L., Marinescu, M., & Dorobanţu, M. (2012) · Europe PMC (PubMed Central) · Cited by 66
Izawa, A., Kashima, Y., Miura, T., Ebisawa, S., Kitabayashi, H., Yamamoto, H., Sakurai, S., Kagoshima, M., Tomita, T., Miyashita, Y., et al. (2014) · Circulation Journal · doi:10.1253/circj.cj-14-0877 · Cited by 43
The emerging concept of “individualized cholesterol-lowering therapy”: A change in paradigm
Lütjohann, D., Stellaard, F., Mulder, M. T., Sijbrands, E. J. G., & Weingärtner, O. (2019) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2019.03.004 · Cited by 44
Self-citationAn update on pharmacotherapies in diabetic dyslipidemia
Gupta, M., Tummala, R., Ghosh, R. K., Blumenthal, C., Philip, K., Bandyopadhyay, D., Ventura, H. O., & DEEDWANIA, P. C. (2019) · Progress in Cardiovascular Diseases · doi:10.1016/j.pcad.2019.07.006 · Cited by 43
Krysiak, R. G., Żmuda, W., & Okopień, B. (2013) · Cardiovascular Therapeutics · doi:10.1111/1755-5922.12057 · Cited by 42
Optimal management of familial hypercholesterolemia: treatment and management strategies
Nemati, M. H., & Astaneh, B. (2010) · Vascular Health and Risk Management · doi:10.2147/vhrm.s8283 · Cited by 42
The metabolic and pharmacologic bases for treating atherogenic dyslipidaemia
Chan, D. C., Barrett, P. H. R., & Watts, G. F. (2013) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2013.10.001 · Cited by 49
My Approach to the Patient With Familial Hypercholesterolemia
Safarova, M. S., & Kullo, I. J. (2016) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2016.04.013 · Cited by 46
Srivastava, R. A. K. (2023) · Cells · doi:10.3390/cells12121648 · Cited by 48
“Statins LDL lowering LDL HMG-CoA Inhibitor [27,28]”
Carotid atherosclerotic plaque stenosis: the stabilizing role of statins
Artom, N., Montecucco, F., Dallegri, F., & Pende, A. (2014) · European Journal of Clinical Investigation · doi:10.1111/eci.12340 · Cited by 42
“As a matter of fact, the progression of the atherosclerotic carotid stenosis can be therapeutically modulated by different lipid-lowering drugs, such as statins, ezetimibe, niacin, torcetrapib [3-12].”
BackgroundNakamura, T., Hirano, M., Kitta, Y., Fujioka, D., Saitō, Y., Kawabata, K., Obata, J., Watanabe, Y., Watanabe, K., & Kugiyama, K. (2012) · Journal of Cardiology · doi:10.1016/j.jjcc.2012.02.005 · Cited by 41
Subclinical Atherosclerosis: Evolving Role of Carotid Intima-Media Thickness
Mookadam, F., Moustafa, S., Lester, S. J., & Warsame, T. A. (2010) · Preventive Cardiology · doi:10.1111/j.1751-7141.2010.00072.x · Cited by 45
Godman, B., Schwabe, U., Selke, G., & Wettermark, B. (2009) · PharmacoEconomics · doi:10.2165/00019053-200927050-00010 · Cited by 41
Statin Therapy with Ezetimibe or Niacin in High-Risk Patients
Kastelein, J. J. P., & Bots, M. L. (2009) · New England Journal of Medicine · doi:10.1056/nejme0908841 · Cited by 41
Self-citationPerspectives on low-density-lipoprotein cholesterol goal achievement
Catapano, A. L. (2009) · Current Medical Research and Opinion · doi:10.1185/03007990802631438 · Cited by 40
Winkler, K., Jacob, S., Schewe, T., Hoffmann, M. M., & Konrad, T. (2011) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2011.10.043 · Cited by 40
“5% reduction in LDL-C was chieved with combination therapy [5].”
MethodVishwanath, R. L., & Hemphill, L. (2013) · Journal of clinical lipidology · doi:10.1016/j.jacl.2013.11.002 · Cited by 41
Taylor, A. J., Villines, T. C., & Stanek, E. J. (2012) · European Heart Journal · doi:10.1093/eurheartj/ehs105 · Cited by 40
“21 In the ENHANCE study, subjects with familial hypercholesterolaemia on statin therapy were randomized to treatment with either ezetimibe or placebo.(19) Ezetimibe had a major LDL-C-lowering effect, with on-treatment LDL-C reduced from 200 to 150 mg/dL.”
MethodDrug Therapy of Hypercholesterolaemia in Children and Adolescents
Braamskamp, M. J. A. M., Wijburg, F. A., & Wiegman, A. (2012) · Drugs · doi:10.2165/11632810-000000000-00000 · Cited by 48
“However, this was probably due to a flawed study design, because most patients had already been treated with statins prior to this study and entered the study with normal baseline IMT.([84]) A small number of short-term studies have investigated the safety and efficacy of ezetimibe in children.”
ResultEzetimibe for the prevention of cardiovascular disease and all-cause mortality events
Zhan, S., Xia, P., Tang, M., Liu, F., Shu, M., & Wu, X. (2017) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd012502 · Cited by 39
Carotid intima-media thickness for the practicing lipidologist
Liviakis, L., Pogue, B. W., Paramsothy, P., Bourne, A., & Gill, E. A. (2009) · Journal of clinical lipidology · doi:10.1016/j.jacl.2009.11.004 · Cited by 42
Ewang-Emukowhate, M., & Wierzbicki, A. S. (2013) · Journal of Cardiovascular Pharmacology and Therapeutics · doi:10.1177/1074248413492906 · Cited by 46
Durga, J., Bots, M. L., Schouten, E. G., Grobbee, D. E., Kok, F. J., & Verhoef, P. (2011) · American Journal of Clinical Nutrition · doi:10.3945/ajcn.110.006429 · Cited by 44
Self-citationCardiovascular complications after transplantation: Treatment options in solid organ recipients
Gillis, K. A., Patel, R. K., & Jardine, A. G. (2013) · Transplantation Reviews · doi:10.1016/j.trre.2013.12.001 · Cited by 39
“concerns that it may alter bioavailability and absorption of fat-soluble drugs, which is of concern in transplant recipients [46–49].”
BackgroundScolaro, B., Kim, H. S. J., & de Castro, I. A. (2016) · Critical Reviews in Food Science and Nutrition · doi:10.1080/10408398.2016.1235546 · Cited by 40
“Combined therapy with ezetimibe and statins appears to have little effect on the progression of atherosclerosis (Kastelein et al., 2008) and only a modest reduction on the occurrence of cardiovascular events (Cannon et al., 2015) in clinical practice.”
BackgroundManagement of dyslipidemia in HIV-infected patients
Sugden, M. C., & Holness, M. J. (2011) · Clinical Lipidology · doi:10.2217/clp.11.25 · Cited by 39
Javed, U., DEEDWANIA, P. C., Bhatt, D. L., Cannon, C. P., Dai, D. W. H., Hernandez, A. F., Peterson, E. D., & Fonarow, G. C. (2010) · American Heart Journal · doi:10.1016/j.ahj.2010.08.041 · Cited by 39
Pedrelli, M., Pramfalk, C., & Parini, P. (2010) · World Journal of Gastroenterology · doi:10.3748/wjg.v16.i47.5958 · Cited by 40
Gooding, H. C., & de Ferranti, S. D. (2010) · Current Opinion in Pediatrics · doi:10.1097/mop.0b013e32833a6e22 · Cited by 41
Spence, J. D. (2010) · Nature Reviews Neurology · doi:10.1038/nrneurol.2010.114 · Cited by 41
Understanding IMPROVE-IT and the cardinal role of LDL-C lowering in CVD prevention
Laufs, U., Descamps, O. S., Catapano, A. L., & Packard, C. J. (2014) · European Heart Journal · doi:10.1093/eurheartj/ehu228 · Cited by 39
“Retrospective analyses of ENHANCE and SHARP suggest that the clinical benefits of ezetimibe therapy fall on the statin-LDL regression line, and therefore most likely are equal to statinmediated LDL lowering.(13,14)”
BackgroundMethodHalcox, J., & Misra, A. (2014) · Metabolic Syndrome and Related Disorders · doi:10.1089/met.2014.0049 · Cited by 45
“This combination did not significantly reduce intima media thickness compared with simvastatin alone, although LDL-C levels were decreased (Table 6).(159) Only 0.”
InfluentialMeijer, P., Oyen, W. J. G., Dekker, D., van den Broek, P. H. H., Wouters, C. W., Boerman, O. C., Scheffer, G. J., Smits, P., & Rongen, G. A. P. J. M. (2009) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.108.179622 · Cited by 38
Zappalla, F. R., & Gidding, S. S. (2009) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2008.11.006 · Cited by 41
Bots, M. L., Palmer, M. K., Dogan, S., Plantinga, Y., Raichlen, J. S., Evans, G. W., O’Leary, D. H., Grobbee, D. E., Crouse, J. R., & METEOR Study Group (2009) · Journal of Internal Medicine · doi:10.1111/j.1365-2796.2009.02073.x · Cited by 38
Self-citationNakajima, N., Miyauchi, K., Yokoyama, T., Ogita, M., Miyazaki, T., Tamura, H., Nishino, A., Yokoyama, K., Okazaki, S., Kurata, T., et al. (2014) · IJC Metabolic & Endocrine · doi:10.1016/j.ijcme.2014.03.001 · Cited by 37
“Our findings were also compared with the results of the ENHANCE study [13].”
ResultDu, R. H., Li, E., Cao, Y., Song, Y., & Tan, R. X. (2011) · Life Sciences · doi:10.1016/j.lfs.2011.06.015 · Cited by 40
The multifaceted therapeutic value of targeting ATP-citrate lyase in atherosclerosis
Verberk, S. G. S., Kuiper, K. L., Lauterbach, M., Latz, E., & den Bossche, J. V. (2021) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2021.09.004 · Cited by 41
Jakulj, L., Vissers, M. N., Groen, A. K., Hutten, B. A., Lütjohann, D., Veltri, E. P., & Kastelein, J. J. P. (2009) · Journal of Lipid Research · doi:10.1194/jlr.m001487 · Cited by 38
Self-citation
Metadata
- Authors
- Kastelein, J. J. P., Akdim, F., Stroes, E. S. G., Zwinderman, A. H., Bots, M. L., Stalenhoef, A. F. H., Visseren, F. L. J., Sijbrands, E. J. G., Trip, M. D., Stein, E. A., Gaudet, D., Duivenvoorden, R., Veltri, E. P., Marais, A. D., & de Groot, E.
- Affiliations
- Amsterdam UMC Location University of Amsterdam (NL)
- University Medical Center Utrecht (NL)
- Radboud University Nijmegen (NL)
- Erasmus MC (NL)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2008-04-03
- Volume
- 358
- Issue
- 14
- Pages
- 1431-1443
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2120289695
- Semantic Scholar
- 0da4a48a4d402878a4b01330a3e43a185140f586
- Cited by
- 1,241
- References
- 34
- Citations by year
- 2026: 8 · 2025: 13 · 2024: 16 · 2023: 20 · 2022: 14 · 2021: 24 · 2020: 27 · 2019: 35 · 2018: 30 · 2017: 38 · 2016: 50 · 2015: 77 · 2014: 91 · 2013: 85 · 2012: 111
- FWCI
- 210.60
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Pure Amsterdam UMC (publishedVersion)
- EUR Research Repository (Erasmus University Rotterdam) (publishedVersion)
- University of Groningen research database (University of Groningen / Centre for Information Technology) (publishedVersion)
- Data Archiving and Networked Services (DANS) (submittedVersion)
- EUR Research Repository (Erasmus University Rotterdam) (submittedVersion)
- RePub (Erasmus University Rotterdam) (submittedVersion, other-oa)
- Radboud Repository (Radboud University) (submittedVersion)
- University of Groningen research database (University of Groningen / Centre for Information Technology) (submittedVersion)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiovascular Health and Disease Prevention
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Cholesterol and Lipid Metabolism
- Keywords
- simvastatin, ezetimibe, familial hypercholesterolemia, LDL cholesterol lowering, atherosclerosis progression, carotid intima-media thickness, femoral artery, cholesterol absorption inhibition, triglycerides, C-reactive protein, statin combination therapy, lipid-lowering therapy, atherosclerotic plaque regression
- MeSH terms
- Ezetimibe, Adult, Anticholesteremic Agents, Azetidines, Carotid Arteries, Cholesterol, Double-Blind Method, Drug Therapy, Combination, Female, Femoral Artery, Humans, Hyperlipoproteinemia Type II, Cholesterol, LDL, Male, Middle Aged, Triglycerides, Ultrasonography, Treatment Outcome, Tunica Intima, Tunica Media, Simvastatin
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.